Nasdaq

Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections

Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets accepting the CE Mark by the ...
Nasdaq

Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests ("2.0") under CE Mark for self-test and professional use

Broad and trusted portfolio of COVID-19 rapid tests feature innovative updates and enhanced performance, building on insights gained throughout the pandemic All tests now work seamlessly with navify® ...